Skin and connective tissue diseases: Skin and Connective Tissue Diseases Atopic Dermatitis
Conditions
Interventions
1. TLO1-UVB
2. UVA
3. Placebo phototherapy
Initial dose of UVA will be 5 J/sq cm, increased to 10 then 15 J/sq cm as tolerated. Initial dose of TLO1 will be increased from 0.4, to 0.6, to 0.9, to 1.2
Sponsors
NHS R&D Regional Programme Register - Department of Health (UK)
Eligibility
Inclusion criteria
Inclusion criteria: Patients, aged 16-65 years with moderate severe atopic dermatitis.
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preliminary work suggests a response should be detectable after 12 treatments. Physical signs of disease activity, overall extent of disease, patient symptoms and quantities of topical steroids used will be assessed, by an observer who is unaware of treatment received, at baseline, after 6, 12, 18 and 24 treatments and 3 months after stopping phototherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed